Luke Timmerman had an interesting piece in Xconomy today coming on the heels of the recently concluded JP Morgan biotech industry get together. He points out that the scales have shifted to put smaller biotechs with an asset on more even footing with Big Pharma when it comes to negotiating over that asset. The reason? More financial options for the little guy now that the IPO market has revived. Plus the run up in stock prices has put more money into the pockets of other potential bidders -- like Celgene, Gilead, etc who can now conceivably pitch better deals than the Big Bad Boys of pharma to give them a run for their money. All this is good for the smaller, formerly less empowered seller and makes for a healthier market environment. Now the little guys can get paid for their innovative efforts and Kevin Kinsella won't have to defend their honor with any more Richard Sherman like rants. As long as this more dynamic market holds then the whole ecosystem will maintain better health. See Xconomy.
Also, Timmerman's gym teacher seems like a real jerk.
Posted by Bruce Lehr Jan 20th 2014.